At this time, the lymphoma - CSCO Autologous Transplant Working Group 2022 Tour - Lymphoma Special Session (Beijing Station) was grandly held

Golden autumn in September, dangui fragrance
.
On September 12, 2022, sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Expert Committee and CSCO Leukemia Expert Committee, and undertaken by the Department of Hematology Medicine of the Fifth Medical Center of the People's Liberation Army General Hospital, the CSCO Autologous Transplant Working Group 2022 Lecture Tour - Lymphoma Special Session (Beijing Station) officially opened
in the form of online and offline cooperation.
Professor Ma Jun of Harbin Institute of Hematology and Oncology and Professor Zhu Jun of Peking University Cancer Hospital served as the chairmen of the conference, and Professor Hu Liangjian and Professor Huang Wenrong of the Fifth Medical Center of the PLA General Hospital served as executive chairmen, inviting relevant experts in the field of lymphoma to discuss and exchange in-depth discussions on
the research progress of lymphoma treatment.

Opening remarks

At the beginning of the meeting, Professor Hu Liangjian, Executive Chairman of the Fifth Medical Center of the PLA General Hospital, presided over the opening ceremony and extended a warm welcome
to the participants.
After that, Professor Ma Jun of Harbin Institute of Hematology and Oncology and Professor Zhu Jun of Peking University Cancer Hospital delivered opening speeches
in turn.
In his speech, Professor Ma Jun expressed the hope that hematology and oncology experts would work together to further develop the field of lymphoma autologous transplantation in China and strive to be in line with international standards
.
Professor Zhu Jun said in his speech that in terms of autologous hematopoietic stem cell transplantation (ASCT), there is still a big gap between China and Western developed countries such as Europe and the United States, and he hopes that in the future, the CSCO Lymphoma Expert Committee, the CSCO Leukemia Expert Committee and the ASCT Working Group will cooperate and jointly promote the development
of this aspect with the help of the CSCO platform.

Professor Hu Liangjian served as the host of the opening ceremony

Professor Ma Jun delivered an opening speech

Professor Zhu Jun delivered an opening speech

Academic Sessions

After the opening ceremony, the academic session followed in full swing
.
The first session was presided over
by Professor Zhang Bolong of Hebei Yanda Ludaopei Hospital.

Professor Zhang Bolong served as the first session moderator

Professor Zhu Jun first reviewed the development of hematopoietic stem cell transplantation (HSCT) in China from 2008 to 2019 and ASCT in various provinces and cities in 2021 in the report "The Current Situation of Lymphoma ASCT in China and the Experience of North-Swollen ASCT in the Treatment of Lymphoma", and also shared the relevant research and experience of Peking University Cancer Hospital in lymphoma treatment in recent years, indicating that the number of ASCT cases in China has increased in recent years, but regional differences are still significant
.
Lymphoma diagnosis and treatment has entered a new era, still need to follow the CSCO lymphoma diagnosis and treatment guidelines, try and work
under the guidelines.
At present, although there are many choices such as new programs and new drugs, the choice of "new" and "expensive" is not the mainstay, and it is more important
for suitable patients to choose ASCT treatment at the right time.
It is hoped that the majority of colleagues will pay more attention to and select ASCT, and work together under the guidance of the guidelines to make ASCT in China move to a new level in quantity and proportion, in addition, as far as possible to improve the efficacy of rescue treatment and pretreatment programs, and reduce the recurrence
after ASCT.

Professor Zhu Jun made a report

In the discussion session, Professor Wang Xiaopei of Peking University Cancer Hospital mentioned that ASCT can improve the survival of lymphoma patients, and in the future transplantation work, we need to strengthen the communication between peers in strengthening the grasp of indications, the selection of pretreatment protocols, the control of the number of CD34+ stem cells after mobilization and collection, post-transplant supportive treatment, etc.
, and promote the MDT model to other centers
.
Professor Gao Wen of Beijing Chaoyang Hospital affiliated to Capital Medical University said that ASCT treatment is mainly for lymphoma and myeloma patients, and the number of cases of myeloma patients receiving ASCT treatment in Beijing Chaoyang Hospital affiliated to Capital Medical University has risen from the initial few cases per year to nearly 80 cases last year, reflecting the improvement of the understanding and acceptance of ASCT value in myeloma patients
.
Subsequently, the participating experts had a heated discussion on the indication grasp of ASCT and the timing of transplantation
.

The second session was chaired
by Professor Song Yuqin of Peking University Cancer Hospital.

Professor Song Yuqin served as the second session moderator

Professor Wang Fengrong of Peking University People's Hospital introduced the current situation
of "HSCT Treatment of Hodgkin Lymphoma" from the aspects of ASCT and allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
First, she mentioned that ASCT remains one
of the standard treatments for relapsed/refractory Hodgkin lymphoma (R/R HL) as recommended by the relevant authoritative guidelines.
Multiple studies have shown that pre-transplant disease status is the most significant factor affecting progression (FFP), and the application of new drugs before and after ASCT can enable more patients to obtain ASCT treatment opportunities, and further improve the efficacy
of transplantation.
Secondly, allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is still the treatment choice for patients with radical treatment of some R/R HL at this stage, and the use of new drugs can enable more patients to benefit from Allo-HSCT, and patients who are not expected to benefit from ASCT are recommended to have Allo-HSCT
early.
In addition, haploid hematopoietic stem cell transplantation (Haplo-HSCT) solves the donor problem on the one hand, and may have stronger anti-tumor effects on the other hand, and is also one of the treatment options after the accumulation of cases in the
future.

Professor Wang Fengrong made a report

During the discussion session, Professor Liu Hui of Beijing Hospital and Professor Li Youhang of the Fifth Medical Center of PLA General Hospital respectively asked questions on "Clinical Application Experience and Safety of Bendamustine Instead of Carmustine in ASCT Pretreatment Scheme" and "Treatment Options for R/R HL Patients", and Professor Wang Fengrong shared
his own clinical experience.

The third session was presided over
by Professor Li Jian of Peking Union Medical College Hospital.

Professor Li Jian served as the moderator of the third session

Professor Jing Hongmei of the Third Hospital of Peking University, in the report "Autologous Hematopoietic Stem Cell Transplantation for B-cell Hodgkin Lymphoma", based on the research results of a number of B-cell lymphoma patients receiving HSCT treatment, pointed out that ASCT still has an important position
in B-cell lymphoma.
With the emergence of new targeted drugs and the emergence of chimeric antigen receptor T cell (CAR-T) therapy, the timing of application of ASCT in lymphoma has changed, for diffuse large B-cell lymphoma (DLBCL), it is recommended that double-strike patients take ASCT as a first-line consolidation, and young high-risk patients are recommended to apply ASCT therapy after relapse; For mantle cell lymphoma (MCL), ASCT is recommended as a first-line consolidation in young able-bodied patients; For indolent non-Hodgkin lymphoma (iNHL), it is recommended that patients with relapsed refractory choose ASCT therapy according to the specific situation; For primary central nervous system lymphoma (PCNSL), ASCT is recommended as first-line consolidation
.
In the selection of high-risk pretreatment regimens for the central nervous system (CNS), Professor Jing Hongmei said that the principles of good antitumor activity, restrictive toxicity of major organs, and no obvious superposition of mutual toxicity should be taken as the principle
.

Professor Jing Hongmei made a report

During the discussion session, Professor Dong Yujun of Peking University First Hospital and Professor Wang Zhiguo of Harbin Institute of Hematology and Oncology made comments, and had a heated discussion
with the guests on issues such as "Molecular Typing of B-cell Lymphoma on ASCT" and "Clinical Practice of DLBCL Hematopoietic Stem Cell Transplantation".

The fourth session was presided over
by Professor Wang Zhao of Beijing Friendship Hospital affiliated to Capital Medical University.

Professor Wang Zhao served as the moderator of the fourth session

Professor Zou Dehui of the Blood Disease Hospital of the Chinese Academy of Medical Sciences brought a wonderful report
on "Hematopoietic Stem Cell Transplantation for Peripheral T-cell Lymphoma (PTCL)".
Professor Zou said that PTCL has heterogeneous and rare characteristics, and the current efficacy is not good
.
For patients with first-line or salvage sensitive PTCL, ASCT therapy is more beneficial, but not all subtypes of patients benefit from ASCT, such as Allo-HSCT can improve survival in some patients with hepatosplenosplenic T-cell lymphoma
.
In addition, Professor Zou Dehui also cited a number of research results to introduce the efficacy
of the first-line combination of new drugs in the treatment of PTCL patients.

Professor Zou Dehui made a report

During the discussion session, Professor Liu Weiping of Peking University Cancer Hospital and Professor Yuan Shunzong of the Fifth Medical Center of PLA General Hospital conducted in-depth discussions with Professor Zou Dehui on issues such as "positive treatment of EBV when collecting peripheral blood", "due to the heterogeneity of PTCL, which types of patients benefit more after receiving transplantation, and whether there are relevant data support", "PTCL is inspired in CAR-T treatment", etc.
, and the academic atmosphere is strong
.

Summary of the meeting

Professor Huang Wenrong summarized the meeting

At the end of the meeting, Professor Zhang Bolong of Hebei Yanda Ludaopei Hospital, Professor Ma Jun of Harbin Institute of Hematology and Oncology, Professor Hu Liangjian and Professor Huang Wenrong of the Fifth Medical Center of the PLA General Hospital summarized
the conference.
They said: The meeting was carried out smoothly, rich in content, and could not be separated from the support of the colleagues, and they looked forward to the fact that after the epidemic improved, everyone could get together offline to discuss and communicate
together.
At present, China's ASCT is far less than Allo-HSCT in quantity, so there is still a long way to go
in this development.
I believe that with the efforts of the CSCO Autologous Hematopoietic Stem Cell Transplantation Working Group and the majority of colleagues, the development of ASCT in China will surely usher in a brilliant future!